期刊
FRONTIERS IN PHARMACOLOGY
卷 6, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fphar.2015.00286
关键词
liposomes; drug delivery; lipid-based drug delivery system; nanotechnology; biological challenges; translation; accelerated blood clearance; complement activation-related pseudoallergy
资金
- University of Newcastle, Hunter Medical Research Institute
- Pharmacy Research Trust of New South Wales
- Rebecca L. Cooper Medical Research Foundation
- NIH [CA 109298, P50 CA083639, P50 CA098258, CA 177909, UH2 TR000943, CA 16672]
- Ovarian Cancer Research Fund, Inc. [CPRIT RP110595, RPI 20211]
- RGK Foundation
- Glider Foundation
- Judi A. Rees Ovarian Cancer Research Fund
- Betty Anne Asche Murray Distinguished Professorship
- Foundation for Women's Cancer, Ovarian Cancer Research Funds
- Cancer Prevention Research Institute of Texas [RP101502, RP101489, RP110595]
The application of liposomes to assist drug delivery has already had a major impact on many biomedical areas. They have been shown to be beneficial for stabilizing therapeutic compounds, overcoming obstacles to cellular and tissue uptake, and improving biodistribution of compounds to target sites in vivo. This enables effective delivery of encapsulated compounds to target sites while minimizing systemic toxicity. Liposomes present as an attractive delivery system due to their flexible physicochemical and biophysical properties, which allow easy manipulation to address different delivery considerations. Despite considerable research in the last 50 years and the plethora of positive results in preclinical studies, the clinical translation of liposome assisted drug delivery platforms has progressed incrementally. In this review, we will discuss the advances in liposome assisted drug delivery, biological challenges that still remain, and current clinical and experimental use of liposomes for biomedical applications. The translational obstacles of liposomal technology will also be presented.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据